| Project/Area Number |
20390433
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
SUGIHARA Kazuhiro Hamamatsu University School of Medicine, 医学部, 准教授 (00265878)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANAYAMA Naohiro 浜松医科大学, 医学部, 教授 (70204550)
ITOH Hiroaki 浜松医科大学, 医学部附属病院, 准教授 (70263085)
MAGATA Yasuhiro 浜松医科大学, 光量子医学研究センター, 教授 (20209399)
KOUMURA Yasuhiro 浜松医科大学, 医学部附属病院, 助教 (50332995)
森島 賀子 浜松医科大学, 医学部, 特任研究員 (70464112)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥19,890,000 (Direct Cost: ¥15,300,000、Indirect Cost: ¥4,590,000)
Fiscal Year 2010: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2009: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2008: ¥12,220,000 (Direct Cost: ¥9,400,000、Indirect Cost: ¥2,820,000)
|
|---|
| Keywords | 婦人科腫瘍学 / 分子標的治療薬 / 腫瘍新生血管 / Annexin 1 / 糖鎖をmimicするペプチド / イメージングシステム / DDS型悪腫瘍治療薬 / 分子標的治療 / 糖鎖 / スプライシングファクター / 腫瘍血管内皮細胞 / ペプチド / リボゾーム / 肺転移 / リポゾーム |
|---|
| Research Abstract |
Among previously identified carbohydrate-mimicry peptides, we found one peptide (Proc Natl Acad Sci USA. 2009), designated as IF7, binds to Annexin 1 (Anxa1), a highly specific tumor endothelial cell surface marker. A synthetic IF7 peptide conjugated with fluorescent Alexa 488 targeted the tumor within several minutes of intravenous injection, which was inhibited by anti-Anxa1 antibody. IF7 conjugated with the anti-cancer drug was injected intravenously into nude mice carrying luciferase-positive tumors produced by human cancer cells. IVIS[○!R] Living 3D Image System showed that IF7-anticancer drug treatment substantially suppressed tumor growth, while in some cases the tumor disappeared. IF7-anticancer drug was effective at low dosages, and mice showed no apparent side effects following drug treatment. Given its extremely specific tumor-targeting activity, IF7 therefore represent a clinically relevant vehicle for anticancer drugs.
|
